• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

年轻乳腺癌女性中 BRCA1 种系突变的形态学预测因子。

Morphological predictors of BRCA1 germline mutations in young women with breast cancer.

机构信息

Department of Pathology, Genetic Epidemiology Laboratory, Victoria, Carlton, Australia.

出版信息

Br J Cancer. 2011 Mar 15;104(6):903-9. doi: 10.1038/bjc.2011.41. Epub 2011 Feb 22.

DOI:10.1038/bjc.2011.41
PMID:21343941
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3065278/
Abstract

BACKGROUND

Knowing a young woman with newly diagnosed breast cancer has a germline BRCA1 mutation informs her clinical management and that of her relatives. We sought an optimal strategy for identifying carriers using family history, breast cancer morphology and hormone receptor status data.

METHODS

We studied a population-based sample of 452 Australian women with invasive breast cancer diagnosed before age 40 years for whom we conducted extensive germline mutation testing (29 carried a BRCA1 mutation) and a systematic pathology review, and collected three-generational family history and tumour ER and PR status. Predictors of mutation status were identified using multiple logistic regression. Areas under receiver operator characteristic (ROC) curves were estimated using five-fold stratified cross-validation.

RESULTS

The probability of being a BRCA1 mutation carrier increased with number of selected histology features even after adjusting for family history and ER and PR status (P<0.0001). From the most parsimonious multivariate model, the odds ratio for being a carrier were: 9.7 (95% confidence interval: 2.6-47.0) for trabecular growth pattern (P=0.001); 7.8 (2.7-25.7) for mitotic index over 50 mitoses per 10 high-powered field (P=0.0003); and 2.7 (1.3-5.9) for each first-degree relative with breast cancer diagnosed before age 60 years (P=0.01).The area under the ROC curve was 0.87 (0.83-0.90).

CONCLUSION

Pathology review, with attention to a few specific morphological features of invasive breast cancers, can identify almost all BRCA1 germline mutation carriers among women with early-onset breast cancer without taking into account family history.

摘要

背景

了解患有新诊断乳腺癌的年轻女性是否存在胚系 BRCA1 突变,这会影响她的临床管理及其亲属的管理。我们旨在寻求一种最佳策略,利用家族史、乳腺癌形态学和激素受体状态数据来识别突变携带者。

方法

我们对 452 名年龄在 40 岁以下患有浸润性乳腺癌的澳大利亚女性进行了基于人群的研究,对这些女性进行了广泛的胚系突变检测(其中 29 名携带 BRCA1 突变)和系统病理学检查,并收集了三代家族史和肿瘤雌激素受体(ER)和孕激素受体(PR)状态。使用多变量逻辑回归识别突变状态的预测因素。使用五重分层交叉验证估计接收者操作特征(ROC)曲线下的面积。

结果

即使在调整了家族史和 ER 和 PR 状态后,具有选定组织学特征的数量也会增加成为 BRCA1 突变携带者的概率(P<0.0001)。从最简约的多变量模型来看,携带者的比值比为:具有小梁生长模式的为 9.7(95%置信区间:2.6-47.0)(P=0.001);有丝分裂指数超过 50 个/10 高倍视野的为 7.8(2.7-25.7)(P=0.0003);每个一级亲属在 60 岁之前被诊断患有乳腺癌的为 2.7(1.3-5.9)(P=0.01)。ROC 曲线下的面积为 0.87(0.83-0.90)。

结论

病理检查,特别注意浸润性乳腺癌的一些特定形态学特征,可以在不考虑家族史的情况下,识别出几乎所有患有早发性乳腺癌的 BRCA1 胚系突变携带者。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb67/3065278/059d8a4a41cb/bjc201141f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb67/3065278/085df0bc3e01/bjc201141f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb67/3065278/059d8a4a41cb/bjc201141f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb67/3065278/085df0bc3e01/bjc201141f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cb67/3065278/059d8a4a41cb/bjc201141f2.jpg

相似文献

1
Morphological predictors of BRCA1 germline mutations in young women with breast cancer.年轻乳腺癌女性中 BRCA1 种系突变的形态学预测因子。
Br J Cancer. 2011 Mar 15;104(6):903-9. doi: 10.1038/bjc.2011.41. Epub 2011 Feb 22.
2
BRCA1 mutations and breast cancer in the general population: analyses in women before age 35 years and in women before age 45 years with first-degree family history.一般人群中的BRCA1突变与乳腺癌:对35岁之前的女性以及有一级家族史的45岁之前的女性的分析。
JAMA. 1998 Mar 25;279(12):922-9. doi: 10.1001/jama.279.12.922.
3
Frequency of BRCA1/BRCA2 mutations in a population-based sample of young breast carcinoma cases.基于人群的年轻乳腺癌病例样本中BRCA1/BRCA2突变的频率。
Cancer. 2000 Mar 15;88(6):1393-402. doi: 10.1002/(sici)1097-0142(20000315)88:6<1393::aid-cncr17>3.0.co;2-p.
4
BRCA1 and BRCA2 mutation status and cancer family history of Danish women affected with multifocal or bilateral breast cancer at a young age.丹麦年轻女性多灶性或双侧乳腺癌患者的BRCA1和BRCA2突变状态及癌症家族史。
J Med Genet. 2001 Jun;38(6):361-8. doi: 10.1136/jmg.38.6.361.
5
Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer.基于人群的早发性乳腺癌系列研究中的乳腺癌和卵巢癌家族史以及BRCA1和BRCA2基因突变
J Natl Cancer Inst. 2001 Aug 15;93(16):1215-23. doi: 10.1093/jnci/93.16.1215.
6
HER-2/neu status and tumor morphology of invasive breast carcinomas in Ashkenazi women with known BRCA1 mutation status in the Ontario Familial Breast Cancer Registry.安大略省家族性乳腺癌登记处中已知BRCA1突变状态的德系犹太妇女浸润性乳腺癌的HER-2/neu状态和肿瘤形态。
Cancer. 2002 Nov 15;95(10):2068-75. doi: 10.1002/cncr.10949.
7
Tumour morphology of early-onset breast cancers predicts breast cancer risk for first-degree relatives: the Australian Breast Cancer Family Registry.早发性乳腺癌的肿瘤形态可预测一级亲属患乳腺癌的风险:澳大利亚乳腺癌家族登记处
Breast Cancer Res. 2012 Aug 28;14(4):R122. doi: 10.1186/bcr3248.
8
Contribution of large genomic BRCA1 alterations to early-onset breast cancer selected for family history and tumour morphology: a report from The Breast Cancer Family Registry.大基因组 BRCA1 改变对家族史和肿瘤形态选择的早发性乳腺癌的贡献:来自乳腺癌家族登记处的报告。
Breast Cancer Res. 2011 Jan 31;13(1):R14. doi: 10.1186/bcr2822.
9
The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations: a population-based study.有和没有BRCA1或BRCA2种系突变的40岁之前发病的女性乳腺癌的组织学表型:一项基于人群的研究。
Cancer. 1998 Dec 1;83(11):2335-45.
10
Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer.649例卵巢癌患者群体中胚系BRCA1和BRCA2基因突变的患病率及外显率
Am J Hum Genet. 2001 Mar;68(3):700-10. doi: 10.1086/318787. Epub 2001 Feb 15.

引用本文的文献

1
Survival After Development of Contralateral Breast Cancer in Korean Patients With Breast Cancer.韩国乳腺癌患者对侧乳腺癌发生后的生存情况。
JAMA Netw Open. 2023 Sep 5;6(9):e2333557. doi: 10.1001/jamanetworkopen.2023.33557.
2
PLA2G7/PAF-AH as Potential Negative Regulator of the Wnt Signaling Pathway Mediates Protective Effects in BRCA1 Mutant Breast Cancer.PLA2G7/PAF-AH 作为 Wnt 信号通路的潜在负调节剂,介导 BRCA1 突变型乳腺癌的保护作用。
Int J Mol Sci. 2023 Jan 3;24(1):882. doi: 10.3390/ijms24010882.
3
The Homologous Recombination Deficiency Scar in Advanced Cancer: Agnostic Targeting of Damaged DNA Repair.

本文引用的文献

1
Incorporating tumour pathology information into breast cancer risk prediction algorithms.将肿瘤病理学信息纳入乳腺癌风险预测算法中。
Breast Cancer Res. 2010;12(3):R28. doi: 10.1186/bcr2576. Epub 2010 May 18.
2
Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy.BRCA1 和 BRCA2 基因突变携带者可手术乳腺癌的局部治疗:保乳术与乳房切除术的比较。
Breast Cancer Res Treat. 2010 Jun;121(2):389-98. doi: 10.1007/s10549-010-0894-z. Epub 2010 Apr 22.
3
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.
晚期癌症中的同源重组缺陷印记:对受损DNA修复的非特异性靶向作用
Cancers (Basel). 2022 Jun 15;14(12):2950. doi: 10.3390/cancers14122950.
4
A novel germline BRCA1 mutation identified in a family with hereditary breast and ovarian cancer syndrome.在一个遗传性乳腺癌和卵巢癌综合征家族中鉴定出一种新型的种系BRCA1突变。
Clin Med Insights Oncol. 2021 Jul 2;15:11795549211028569. doi: 10.1177/11795549211028569. eCollection 2021.
5
Prognostic Impact of and Mutations on Long-Term Survival Outcomes in Egyptian Female Breast Cancer Patients.埃及女性乳腺癌患者中[具体基因]突变对长期生存结果的预后影响
Biology (Basel). 2021 Jun 22;10(7):566. doi: 10.3390/biology10070566.
6
Promoter Hypermethylation and Expression Changes of BRCA1 Gene in a Cohort of Sporadic Breast Cancer Cases among Pakistani Population.BRCA1 基因启动子甲基化与巴基斯坦散发性乳腺癌病例群表达变化。
Asian Pac J Cancer Prev. 2020 Aug 1;21(8):2395-2401. doi: 10.31557/APJCP.2020.21.8.2395.
7
in Breast and Ovarian Cancers.在乳腺癌和卵巢癌中。
Int J Mol Sci. 2020 May 28;21(11):3850. doi: 10.3390/ijms21113850.
8
Genome-wide DNA methylation assessment of 'BRCA1-like' early-onset breast cancer: Data from the Australian Breast Cancer Family Registry.基于澳大利亚乳腺癌家族登记处的数据进行“BRCA1 样”早发性乳腺癌的全基因组 DNA 甲基化评估。
Exp Mol Pathol. 2018 Dec;105(3):404-410. doi: 10.1016/j.yexmp.2018.11.006. Epub 2018 Nov 10.
9
Heritable DNA methylation marks associated with susceptibility to breast cancer.与乳腺癌易感性相关的可遗传DNA甲基化标记。
Nat Commun. 2018 Feb 28;9(1):867. doi: 10.1038/s41467-018-03058-6.
10
Performing and Declining PGD: Accounts of Jewish Israeli Women Who Carry a BRCA1/2 Mutation or Partners of Male Mutation Carriers.实施和拒绝植入前基因诊断:携带BRCA1/2突变的以色列犹太女性或男性突变携带者伴侣的经历
J Genet Couns. 2017 Oct;26(5):1070-1079. doi: 10.1007/s10897-017-0087-6. Epub 2017 Mar 6.
对携带BRCA突变的肿瘤中聚(ADP - 核糖)聚合酶的抑制作用。
N Engl J Med. 2009 Jul 9;361(2):123-34. doi: 10.1056/NEJMoa0900212. Epub 2009 Jun 24.
4
BRCA1 and BRCA2 mutation carriers in the Breast Cancer Family Registry: an open resource for collaborative research.乳腺癌家族登记处中的BRCA1和BRCA2突变携带者:一个用于合作研究的开放资源。
Breast Cancer Res Treat. 2009 Jul;116(2):379-86. doi: 10.1007/s10549-008-0153-8. Epub 2008 Aug 14.
5
Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics.预测携带BRCA1或BRCA2基因突变的可能性:利用英国基因诊所的数据对BOADICEA、BRCAPRO、IBIS、Myriad和曼彻斯特评分系统进行验证
J Med Genet. 2008 Jul;45(7):425-31. doi: 10.1136/jmg.2007.056556. Epub 2008 Apr 15.
6
The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions.乳腺癌和卵巢癌遗传易感性的BOADICEA模型:更新与扩展
Br J Cancer. 2008 Apr 22;98(8):1457-66. doi: 10.1038/sj.bjc.6604305. Epub 2008 Mar 18.
7
Prognosis of breast cancer in carriers of BRCA1 and BRCA2 mutations.
N Engl J Med. 2007 Oct 11;357(15):1555; author reply 1556. doi: 10.1056/NEJMc072301.
8
Validity of models for predicting BRCA1 and BRCA2 mutations.预测BRCA1和BRCA2基因突变模型的有效性。
Ann Intern Med. 2007 Oct 2;147(7):441-50. doi: 10.7326/0003-4819-147-7-200710020-00002.
9
Validation study of the LAMBDA model for predicting the BRCA1 or BRCA2 mutation carrier status of North American Ashkenazi Jewish women.用于预测北美阿什肯纳兹犹太女性BRCA1或BRCA2突变携带者状态的LAMBDA模型的验证研究。
Clin Genet. 2007 Aug;72(2):87-97. doi: 10.1111/j.1399-0004.2007.00841.x.
10
Microsatellite instability markers for identifying early-onset colorectal cancers caused by germ-line mutations in DNA mismatch repair genes.用于识别由DNA错配修复基因种系突变引起的早发性结直肠癌的微卫星不稳定性标志物。
Clin Cancer Res. 2007 May 15;13(10):2865-9. doi: 10.1158/1078-0432.CCR-06-2174.